Who Benefits Most?

Patients on medication with unresolved symptoms

Many patients with autoimmune diseases are able to sustain clinical remission and control symptoms through prescription therapies that prevent the immune system from attacking different cell types in response to exposome triggers.

Patients with inadequate response to these therapies, also called “non-responders”, remain vulnerable to their exposome, resulting in uncontrolled symptoms such as pain and stiffness in joints and muscles, weakness, brain fog, digestive issues, sleep disorders, tremors, headaches and more.

On average 40% of autoimmune rheumatic patients in randomized controlled trials are non-responders as defined by drug intolerance or lack of minimum joint improvement.

This number rises above 65% in the real world, with increased medication and healthcare required in addition to autoimmune therapy.

What is the exposome?

The exposome represents the totality of all internal biological and external environmental factors individuals are exposed to throughout their life. Such factors can include diet, sleep, stress, air and water quality, climate and exposure to mold, toxins, pathogens or UV light.

No two exposomes are the same, not even with identical twins.

There can be a perfect storm of triggers that leads to a deterioration in health. The type, timing and frequency of exposures to potential triggers all play a role.

Why Personalized Trials & Care?

The risks of trial and error

For people with unpredictable and debilitating symptoms, trial & error between additional medications, supplements and diets can lead to even more exposure to hidden triggers, with no way to know what helps and what hurts.

Understanding how hidden triggers, cross-reactivities, and interactions in the exposome, directly impact one's own symptoms, is critical to preventing and managing flares.

Trial-and-Error-Image

From Trial & Error to Personalized Trials & Care

Mymee replaces high risk trial & error with a clinically validated solution that includes personalized trials & care.

Mymee's SOC-2 compliant and peer-reviewed digital care solution directly identifies factors that worsen or alleviate symptoms via a personalized trial process, including specialized health coaches, data platform and mobile application.

A self-evidence-based methodology is critical for patients to directly correlate their symptoms to unique triggers hidden within the exposome.

Patients lower health risks, learn to reduce, predict and control flares, and experience 90% average improvement in ability to work with their physicians.

The 4 steps of the Mymee personalized trial & care solution

	Onboarding & exposome assessment Patient matched to a specialized health coach. Baseline exposome data capture and analysis (e.g. symptoms, food, supplements, Rx/pharmacogenetics, vaccine, infection, surgical history, environment). Health risk and symptom prioritization.
	Pharmacist consult & HCP reporting If medication risk warrants, Mymee specialized health coach coordinates a pharmacist consultation to review Rx/supplements and pharmacogenetics. Any drug tapering or optimization recommendations are shared with physician and patient, and incorporated into the personalized trial & care solution.
	Coach-led personalized trial & care Highly specialized autoimmune health coaches guide weekly trigger analysis and care sessions. Symptoms and potential triggers are easily captured by the patient through a personalized mobile app (minutes per day). Triggers and evidence-based health and nutrition adjustments monitored to directly correlate what alleviates or worsens symptoms. Daily activities expanded with continuous monitoring until achieving health objectives. Final risk assessment identifies ongoing care needs and tapering support, if any.
	Affordable personalized care as needed Patients who remain at risk from unresolved symptoms, triggers and comorbidities have access to low cost personalized support to minimize flares. PGx report enables patients and their physicians to avoid known medication interactions and genetic risk factors.

Specialized Health Coach Expertise

Certified autoimmune health coaches are trained on Mymee’s proprietary personalized trial & care platform to analyze unique trigger-symptom correlations and guide each person through their own personalized trial process.

Each coach has experience reclaiming their own health from autoimmune disease and brings deep knowledge and training helping patients gain control of unpredictable flares.

Mymee's personalized trials & care expertise includes:

Outcomes & Research

Peer-reviewed studies

Mymee's personalized trial & care platform is clinically validated for patients with unmanageable symptoms and complex sensitivities to their exposome, resulting from ≥1 autoimmune disease or long COVID.

In peer-reviewed studies, patients with moderate to severe symptoms achieved statistically significant and clinically meaningful improvement across all ten HRQoL PROMIS® domains*:

Social roles
Cognitive function
Managing symptoms
Physical function
Anxiety
Depression
Fatigue
Pain interference
Sleep disturbance
Pain intensity

Enrolled patients reported a mean improvement across 59 patient-reported symptoms of 40% in an average of 17 weeks.

The most commonly reported symptoms at study enrollment included*:

Fatigue
Pain & aches in joints
Limitation of movement
Feeling of weakness
Pain or cramps in muscles
Diarrhea and/or constipation
Night waking
Brain fog (poor memory, confusion)
Anxiety
Headaches
Faintness/dizziness
Numb or tingly sensation
Intestinal or abdominal pain
Breathing difficulties
Tremor or restless leg

The most frequent diseases in the studies included:

Rheumatoid Arthritis
Lupus (SLE)
Psoriatic Arthritis
Ankylosing spondylitis
Long COVID
Mixed connective tissue disease
Crohn’s and ulcerative colitis, plus rheumatic symptoms
Psoriasis, plus rheumatic symptoms
Multiple sclerosis plus rheumatic symptoms

Additional research and analysis has demonstrated that personalized trials and care with Mymee has enabled patients to:

Improve their ability to work with their doctor to manage symptoms
Achieve statistically significant improvements in ten health-related quality of life (HRQoL) domains such as fatigue, pain, anxiety and cognitive function
Improve their feelings of hopelessness by an average of 75%

* Sources: 1. Peer-reviewed study of personalized trials in autoimmune population, Rheumatic & Musculoskeletal Open Journal, May 2023; 2. Symptoms-59 survey, weighted mean change (n=182 personalized trials); 3. A Self-Evidence-Driven Personalized Trial and Care Program Correlates the Exposome to Persistent Autoimmune Rheumatic Symptoms and Improves Health-Related Quality of Life; (n=163 personalized trials); poster, IMF conference, 2023.

Mymee’s specialty is working with individuals who

Have one or more diagnosed rheumatic autoimmune diseases such as Lupus, RA, Ankylosing Spondylitis, Psoriatic Arthritis or Mixed Connective Tissue Disease

Report active joint pain & other systemic rheumatic symptoms associated with rheumatic long COVID & autoimmune diseases like Psoriasis, Inflammatory Bowel Disease or Hashimoto's

Managing > 10 unique unpredictable symptoms, not unusual with long COVID & mixed autoimmune disease diagnosis

Are adhering to presciption NSAIDs, steroids, conventional and/or biologic DMARDS & still experiencing disease flares

Already tried supplements, autoimmune diets & removing gluten, and are still managing significant unpredictable sysmptoms

Are at a crossroads with their treatment & working with their doctor to decide what's next

The Mymee Method